Immunotherapies are growing traction in both the human and veterinary market as a sole or adjunct treatment to chemotherapy and/or radiation.
With over 10 years of supporting research, VetiVax is a whole cell tissue vaccine that allows for a variety of tumor antigens to be presented to the immune system. This abundant choice of antigens increases the likelihood of a successful response.
Multiple cancer types have been proven to have immunogenic properties. VetiVax combines the patient’s tumor cells with our proprietary bulking agent, MIM, which contains all of the necessary components to potentiate an effective immune response against fighting the cancer.
Suckow MA, Rosen ED, Wolter WR, Sailes V, Jeffrey R, Tenniswood M. Prevention of human PC-346C prostate cancer growth in mice by a xenogeneic vaccine. Cancer Immunology Immunotherapy 56:1275-1283, 2007.
Suckow MA, Heinrich JE, Rosen ED. Tissue vaccines for cancer. Expert Review of Vaccines 6:925-937, 2007.
Suckow MA, Wheeler JD, Wolter WR, Sailes V, Yan M. Immunization with a tissue vaccine enhances the effect of irradiation of prostate tumors. In Vivo 22:171-177, 2008.
Suckow MA, Hall P, Wolter W, Sailes V, Hiles MC. Use of an extracellular matrix material as a vaccine carrier and adjuvant. Anticancer Research 28:2529-2534, 2008.
Suckow MA, Wolter WR, Sailes VT. Inhibition of prostate cancer metastasis by administration of a tissue vaccine. Clinical & Experimental Metastasis 25:913-918, 2008.
Suckow MA, Hall P, Hiles MC. Tissue vaccines for prevention and treatment of prostate cancer. Proceedia in Vaccinology 1:124-126, 2009.
Suckow MA. Cancer vaccines: harnessing the potential of anti-tumor immunity. The Veterinary Journal, 198:28-33, 2013.
Suckow MA, Ritchie R, and Overby A. 2011. Extracellular matrix adjuvant for vaccines. Pp. 441-458. In: Pignatello, R. (ed.), Biomaterials: Applications for Nanomedicine, Intech, Rijeka, Croatia.